- FibroBiologics Announces 2024 Annual Meeting of Stockholders
- FibroBiologics Files 2024 First Quarter Report
- FibroBiologics to Present at the BIO International Convention 2024
- FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids
- FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office
- FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA
- FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 32.72m |
Free float | 22.79m |
P/E (TTM) | -- |
Market cap | 371.36m USD |
EPS (TTM) | -0.9149 USD |
--
More ▼